XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.62

+1.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert S. who wrote (8446)	1/23/1999 3:09:00 AM
From: aknahow	Read Replies (2) of 17367

Thought Cacaito just got through pointing out he thought the Trauma trial was not as well designed as the perfusion trial. While one cannot rule out marginal therapeutic efficacy, if this was the case it would be more probable that the trial would have ended in 1998 due to reaching the specified level of deaths or simply because the DSMB would have said, Neuprex is not working, end the trial. Fail to see why you are so worried that the trial might be successful, since, as you have posted several times, there is no market anyway.<g>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next